Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Quazepam: hypnotic efficacy and side effects.

A Kales1

  • 1Sleep Research and Treatment Center, Hershey Medical Center, Hershey, PA 17033.

Pharmacotherapy
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A reassessment of triazolam.

The International journal of risk & safety in medicine·2013
Same author

Excessive daytime sleepiness in a general population sample: the role of sleep apnea, age, obesity, diabetes, and depression.

The Journal of clinical endocrinology and metabolism·2005
Same author

Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines.

The Journal of clinical endocrinology and metabolism·2004
Same author

Insomnia in central Pennsylvania.

Journal of psychosomatic research·2002
Same author

Chronic insomnia is associated with a shift of interleukin-6 and tumor necrosis factor secretion from nighttime to daytime.

Metabolism: clinical and experimental·2002
Same author

Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications.

The Journal of clinical endocrinology and metabolism·2001
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
Same journal

Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation.

Pharmacotherapy·2026
Same journal

Quantifying the Serum Magnesium Response and Predictors of Response Following Intravenous Magnesium Replacement in Critically Ill Patients.

Pharmacotherapy·2026
See all related articles

Quazepam, a long-acting benzodiazepine hypnotic, effectively treats insomnia with sustained efficacy and minimal rebound effects. It offers a favorable side effect profile compared to other benzodiazepines, with daytime sedation being the primary concern.

Area of Science:

  • Pharmacology
  • Sleep Medicine

Background:

  • Quazepam is a benzodiazepine hypnotic used for insomnia.
  • It has long elimination half-lives for the parent compound and its active metabolites.
  • Recommended doses are 15 mg for adults and 7.5 mg for geriatric patients.

Purpose of the Study:

  • To evaluate the efficacy and safety of quazepam in treating insomnia.
  • To compare quazepam's effectiveness and side effect profile with other benzodiazepines like triazolam and temazepam.

Main Methods:

  • Review of sleep laboratory studies and clinical trials.
  • Analysis of pharmacokinetic data regarding elimination half-lives.
  • Comparison of clinical outcomes and adverse events with other hypnotics.

Main Results:

Related Experiment Videos

  • Quazepam (15 mg) is efficacious for inducing and maintaining sleep in short-term and continued use.
  • The 7.5 mg dose is also effective, particularly in the elderly.
  • No rebound insomnia or anxiety observed upon withdrawal; minimal carryover effects.
  • Daytime sedation is the main side effect, manageable with dose adjustment.
  • Quazepam maintains efficacy with continued use, unlike triazolam and temazepam which show tolerance.

Conclusions:

  • Quazepam is an effective adjunctive treatment for insomnia with sustained efficacy.
  • It demonstrates a superior safety profile compared to triazolam and temazepam, with fewer severe side effects.
  • Quazepam's long elimination half-life contributes to its sustained effectiveness and lack of rebound phenomena.